Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN045
- Development stage
- Unknown
- Lead developer
- SSY Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SYN045 is a small molecule drug developed by Shijiazhuang No. 4 Pharmaceutical Co., Ltd. It acts as a highly selective agonist of the prostacyclin (PGI2) receptor, also known as the prostaglandin I2 receptor. The drug is being investigated primarily for the treatment of pulmonary arterial hypertension (PAH). Preclinical studies have demonstrated that SYN045 has high targeting selectivity and favorable safety characteristics. As of March 2025, it is in Phase 1 clinical trials, with ongoing studies evaluating its safety, tolerability, pharmacokinetics, and food effects in healthy adult subjects[1][2][4][9].
- Brand names
- SYN045SYN-045SYN 045
- Other names
- SYN045SYN-045SYN 045
02
Targets
PTGIR (Prostanoid IP Receptor)
Beyond the preview
Go deeper on SYN045.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN045.